Puma Biotechnology vs Zymeworks
PBYI and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PBYI and ZYME compare
Zymeworks is the larger company, worth 5.0 times as much as Puma Biotechnology ($1.9B against $379M).
Puma Biotechnology grew revenue faster over the last twelve months (−2.9% versus −69.8% for Zymeworks).
Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −404% at Zymeworks.
Puma Biotechnology scores higher on the StockData Score (14 against 5 for Zymeworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PBYI | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $379M | $1.9B |
| Share price | $7.34 | $26.45 |
| Change, 1 year | 48.3% | 43.0% |
| Change, 5 years | 128% | 35.6% |
| Beta (5Y) | 1.28 | 0.28 |
| Employees | 179 | 264 |
| StockData Score | ||
| Total score | 14 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 5 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.1× | – |
| P/S | 1.6× (better) | 50.6× |
| P/B | 2.7× (better) | 23.4× |
| EV/EBITDA | 7.1× | – |
| P/FCF | 9.2× | – |
| FCF yield | 10.9% (better) | −6.4% |
| Fair value | $8.88 | $3.39 |
| Margin of safety | 17.4% (better) | −680% |
| Growth | ||
| Revenue growth (TTM) | −2.9% (better) | −69.8% |
| Revenue growth, 5Y average | 0.29% | 22.2% (better) |
| Net income growth (TTM) | −44.9% | – |
| EPS growth (TTM) | −46.9% | – |
| Profitability | ||
| Gross margin | 74.8% | – |
| Operating margin | 13.2% (better) | −419% |
| Net margin | 11.6% (better) | −404% |
| FCF margin | 17.8% (better) | −325% |
| Return on equity | 22.0% (better) | −72.3% |
| Return on invested capital | 42.7% (better) | −179% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Net debt / EBITDA | −2.12 | – |
| Interest coverage | 8.6× | – |
| Current ratio | 2.91 | 6.32 (better) |
| Altman Z-score | −2.78 | −1.01 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 9.0% |
| Shareholder yield | 0.00% | 9.0% (better) |
| Ownership | ||
| Held by institutions | 74.9% | 98.1% |
| Held by insiders | 18.9% | 58.9% |
| Insider net buying, 12 months | −$2.1M (better) | −$5.0M |
| Short interest, % of float | 10.3% | 20.3% |
Go deeper
- PBYI stock overview
- PBYI income statement
- PBYI valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.